[SCHEDULE 13G] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Paradigm BioCapital and related entities reported beneficial ownership of 3,027,977 shares of Agios Pharmaceuticals common stock, representing 5.2% of the outstanding class. The filing shows the position as of the close of business on August 21, 2025 and explains that the total includes 2,827,977 shares directly held (2,493,645 by Paradigm BioCapital International Fund Ltd. and 334,332 by a separately managed account) plus 200,000 shares underlying call options exercisable within 60 days (176,300 attributable to the Fund and 23,700 to the Account). The reporting group bases percentages on 58,101,518 shares outstanding as of July 25, 2025. The filing states these holdings are not intended to influence control of the issuer and includes a joint filing agreement.

Positive

• Transparent disclosure of a >5% position in AGIO, enabling market participants to understand major ownership
• Includes options exercisable within 60 days, clarifying near-term potential increases in share count attributable to the filer
• Clear attribution of holdings among Fund, Account, Adviser, Adviser GP and individual, aiding governance transparency

Negative

• None.

Insights

Financial Analyst

TL;DR: A passive investor group disclosed a >5% stake in Agios, combining share holdings and near-term exercisable options.

The Schedule 13G shows Paradigm BioCapital structures hold 3,027,977 shares, equal to 5.2% of Agios, including 200,000 shares from call options exercisable within 60 days. For investors, a filer crossing the 5% threshold is material because it signals a significant stake without intent to change control, per the certification. The position is sizable relative to the 58.1 million shares outstanding but remains below levels typically associated with control. The disclosure clarifies ownership attribution among the Fund, an Account, the Adviser, the Adviser GP and an individual managing member.

Corporate Governance Expert

TL;DR: This is a routine passive ownership disclosure that notifies the market of a meaningful stake but disclaims control intent.

The filing is a standard Schedule 13G rather than a 13D, indicating the reporting persons represent a passive investor group. The certification explicitly states the securities were not acquired to influence control, reducing immediate governance concerns. The breakdown of sole voting and dispositive power attributed to the Adviser and related entities is clearly reported, supporting transparency around who can direct voting or disposition of the shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Agios Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

00847X104

(CUSIP Number)

08/21/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,027,977.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,027,977.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,027,977.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,027,977.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,027,977.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,027,977.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Limited liability company

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,027,977.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,027,977.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,027,977.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,669,945.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,669,945.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,669,945.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Agios Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 88 Sidney Street, Cambridge, MA 02139
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 00847X104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on the Event Date of August 21, 2025 and which includes 2,827,977 Common Shares (2,493,645 held by the Fund and 334,332 held by the Account) and an additional 200,000 Common Shares (176,300 attributable to the Fund and 23,700 attributable to the Account) underlying call options that were as of such date exercisable within 60 days.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 58,101,518 shares of Common Stock outstanding as of July 25, 2025 as reported in the Issuer's Form 10-Q filed on July 31, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/28/2025

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/28/2025

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	08/28/2025

Paradigm BioCapital International Fund Ltd.

Signature:	David K. Kim / Authorized Signatory
Name/Title:	N/A
Date:	08/28/2025

Exhibit Information

99.1 - Joint Filing Agreement

FAQ

What stake in AGIO did Paradigm BioCapital report?

The filing reports beneficial ownership of 3,027,977 shares, equal to 5.2% of Agios' common stock.

Does the reported position include options or derivatives?

Yes. The amount includes 200,000 shares underlying call options exercisable within 60 days (176,300 attributable to the Fund and 23,700 to the Account).

What is the breakdown of direct holdings between the Fund and managed account?

The filing states 2,493,645 shares are held by Paradigm BioCapital International Fund Ltd. and 334,332 shares are held by a separately managed account.

On what share count is the percentage ownership based?

Percentages are based on 58,101,518 shares outstanding as of July 25, 2025 per the issuer's disclosure.

Did the filers state any intent to influence control of Agios?

No. The certification states the securities were not acquired and are not held to change or influence control of the issuer.